Australasian Menopause Society - Studies Recruiting

Home

Studies Recruiting

Research studies that are related to menopause and midlife women's health may be undertaken by Australasian Menopause Society members.

Women who would like to volunteer to participate in any study outlined below should contact the nominated person from the study directly.

Disclaimer

The list of studies currently recruiting is published by the Australasian Menopause Society as a service to its members. The AMS accepts no responsibility for the accuracy of the information contained in the description of the studies or the consequences of any person becoming a study subject. These studies are not endorsed by the AMS, however all listed studies have produced Ethics Committee approval prior to being accepted for inclusion on the AMS website.

Menopause and Exercise

Description of Study
The main objective of this study is to examine the exercise behaviour of women during menopause. We are keen to understand why participatory rates are at the lowest in women in the menopausal state and thereafter during the lifespan. Broadly, this study aims to assess the relative impact of different aspects of the menopause on physical activity participation, and attempts to differentiate the general effects of psychological and physical symptoms, as well as those related to aging on exercise participation

Inclusion Criteria
Women who meet the criteria for peri-menopause and post menopausal stages, as identified by the National Institutes of Health (2002): PERI-MENOPAUSE is defined as to the period that starts from the time of menstrual irregularity and ends 1 year after the final menstrual period, women who reported irregularity in their menstrual cycles and had had no period for between 3 and 12 months; POSTMENOPAUSE is defined as the period following peri-menopause, i.e. postmenopausal after 12 months without a menstrual period; and pre-menopause refers to the entire period before peri-menopause. Only women in the peri- and post-menopausal stages will be invited to participate. It is presumed that the volunteers will be English speaking. Furthermore, women who are currently on HRT or have been taking HRT in the last 6 months will be excluded as well as women with serious medical condition (e.g. cancer) or psychological conditions (e.g. depression).

Ethics Approval
Ethical approval was granted from Victoria University's Human Research Ethics Committee.

Geographical location of study
websurvey: https://www.surveymonkey.com/s/exercise_menopause

Principal Investigators
Dr Erika Borkoles & Professor Lily Stojanovska

Contact details
Dr Erika Borkoles
email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
tel: 03 9919 5977
Content updated 2 June 2011

Last Updated (Thursday, 02 June 2011 10:19)

The effect of S-Equol on Hot Flushes in Menopausal Women

Study Title:
Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment with AUS 131 (S Equol) on Vasomotor Symptoms in Menopausal Patients

Description of the study:
This study is to investigate the effects and safety of a new investigational drug preparation, S-equol, in the treatment of hot flushes and night sweats.
In nature, S-equol is produced from soy. Previous studies have demonstrated that helps some women soy in reducing these menopausal symptoms.
During the 4 week treatment period participants will receive twice daily treatment with either S-equol 10mg or 50mg or 150mg or placebo

Inclusion criteria:

healthy post menopausal women
suffers from hot flushes and night sweats
BMI < 35
has not used hormonal therapy in the last 3 months

Ethics Approval:
Approval to conduct this study has been given by Family Planning Ethics Committee, approval number R2010-05.

Geographical location of study:
Sydney Centre for Reproductive Health Research,

Family Planning NSW

328-336 Liverpool Road, Ashfield 2131, NSW, Sydney

Principal Investigator:
Dr Edith Weisberg

Contact details:
Sydney Centre for Reproductive Health Research, Family Planning NSW

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Content updated 25 February 2011

Last Updated (Friday, 25 February 2011 09:43)

Testosterone Cognition Study

Description of the study:
The purpose of this study is to assess the effects of Testosterone on Cognition (brain function, including learning and memory) in postmenopausal women. The effects of testosterone will be assessed by the response to various tests of cognition (brain function).The study will run over 6 months and involves applying a transdermal therapy or placebo for this period. Participation will involve 4 visits to the study centre.

Inclusion criteria:
• Aged between 55 -70
• Healthy and Post-menopausal
• Not taking hormonal therapy
• Able to use topical Testosterone

Ethics Approval:
Monash University Human Research Ethics Committee-MUHREC Project Number: CF10/0129 – 2010000046 WHP 2010/8) Project Number: CF09/2520 – 2009001460 WHP 2009/6)

Geographical location of study:
Prahran

Principal Investigator:
Professor Susan Davis

Contact details:
For more information please contact us on: Phone: (03) 99030820 Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Website:http://womenshealth.med.monash.edu.au

Content updated 6 October 2010

Last Updated (Wednesday, 06 October 2010 16:49)

Metformin for the management of insulin resistance in overweight women at midlife

Description of the study:

The purpose of this project is to assess the effects of Metformin on insulin sensitivity (which helps prevent progression to type 2 diabetes), weight loss and lipids such as cholesterol. This study runs for 6 months and involves taking an oral study medication or placebo for this period. The participant is required to visit the study centre 4 times for medical assessments and observations.

Inclusion criteria:
- Aged between 45 and 65 years
- No use of systemic hormones in the past 3 months
- A BMI >30kg/m2 and <40kg/m2 and a waist circumference >88cm
- Post menopausal
- In good health

Ethics Approval:
Monash University Human Research Ethics Committee-MUHREC Project Number: CF10/1417 – 2010000757 (WHP 2010/9)

Geographical location of study:
Prahran

Principal Investigator:
Professor Susan Davis

Contact details:
For more information please contact us on: Phone: (03) 9903 0820 Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Website:http://womenshealth.med.monash.edu.au

Content updated 6 Oct5ober 2010

Last Updated (Wednesday, 06 October 2010 16:53)

International Breast Cancer Intervention Study II

Description

The International Breast Cancer Intervention Study II (IBIS II) is the first study to investigate whether the breast cancer treatment drug anastrozole can prevent breast cancer from occurring in postmenopausal women at higher risk of developing the disease. There are currently 21 countries around the world participating in this study. 10,000 women are needed worldwide and accrual passed 5100 in December 2009. Women will be required to take a daily tablet for five years and visit a clinic twice in the first year and once every year following.

The study is coordinated in Australia and New Zealand by the Australian New Zealand Breast Cancer Trials Group. The ANZ BCTG is a not-for-profit organisation and is Australia's national organisation dedicated to breast cancer research

Inclusion Criteria

Aged between 40 and 70
Postmenopausal
At increased risk of breast cancer due to a family history or other risk factors
Must not have had invasive breast cancer
Women who have had DCIS diagnosed within the last 6 months may be eligible to join a sub-study of IBIS-II, investigating treatments for DCIS.

Geographical Location of Study

The study is currently available at 28 sites in Australia and 4 sites in New Zealand.

Principal Investigator

Australia and New Zealand - Study Chairman Professor John Forbes, Study Co-Chairman Professor John Simes. Each site has its own dedicated Principal Investigator.

Contact Details

Women who are interested in participating in this study should contact the relevant freecall number and leave their details. A study coordinator from their nearest site will contact them.

Australia – 1800 640 709
New Zealand – 0800 888 656
Visit www.anzbctg.org for further information.

Last Updated (Thursday, 21 January 2010 18:09)

Metformin for the management of insulin resistance in overweight women at midlife

Last Updated (Wednesday, 06 October 2010 16:53)